It was concluded that ERα/PR-negative breast cancers might be treated by blocking ER activity via estrogen withdrawal with aromatase inhibitors by targeted ER degradation, or by combined therapy that assumes both ER and growth factor signaling pathway [73]. This evidence concerns the gene CYP19A1 and breast carcinoma.